Cancer immunotherapies, particularly the use of immune checkpoint inhibitors (ICIs), have significantly transformed the clinical management of HCC in recent years Bevacizumab (anti‐VEGF) and Atezolizumab (anti‐PD1), when combined, have been demonstrated to be more effective than the first‐line therapy, sorafenib.[5] Despite these advancements, HCC remains one of the most challenging cancers due to its frequent recurrence and medication resistance. This evidence concerns the gene VEGFA and cancer.